Nuvectis Pharma (NVCT) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.30
- EPS estimate
- −$0.25
- EPS surprise
- −19.19%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 5, 2025
Nuvectis Pharma reported Q2 2025 results on August 5, 2025. It posted a loss of $0.30 per share, wider than the $0.25 loss analysts expected, a 19.19% miss. The table shows no revenue and no revenue estimate for the company. A year earlier, in Q2 2024, the loss was $0.26 per share, so the quarterly loss widened by about 15%.
The record covers 15 quarters, from Q4 2021 to Q2 2025, and every one was a loss. Quarterly losses ranged from $0.24 per share in Q3 2024, the smallest here, to $0.52 in Q4 2021, the largest. For full fiscal years, the annual loss narrowed from $1.51 per share in 2022 to $1.43 in 2023 and $1.10 in 2024. The first half of 2025 added up to a loss of $0.57, against $0.51 in the first half of 2024. Against estimates, Nuvectis beat the EPS estimate four times, matched it twice and missed it nine times.
The table has no results after Q2 2025. In earlier years, Nuvectis reported Q3 results between November 5 and November 8. Any newer report will show whether the quarterly loss returns toward the $0.24 to $0.27 range seen in 2024 and early 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 5, 2025 | −$0.25 | −$0.30 | −19.19% | $0.00 | SEC |
| Q1 2025 | May 6, 2025 | −$0.25 | −$0.27 | −6.30% | $0.00 | SEC |
| Q4 2024 | Feb 25, 2025 | −$0.25 | −$0.35 | −38.18% | $0.00 | SEC |
| Q3 2024 | Nov 5, 2024 | −$0.25 | −$0.24 | +4.91% | $0.00 | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.26 | −$0.26 | +0.00% | $0.00 | SEC |
| Q1 2024 | May 7, 2024 | −$0.40 | −$0.25 | +36.98% | $0.00 | SEC |
| Q4 2023 | Mar 5, 2024 | −$0.41 | −$0.41 | +0.00% | $0.00 | SEC |
| Q3 2023 | Nov 8, 2023 | −$0.34 | −$0.37 | −8.03% | $0.00 | SEC |
| Q2 2023 | Aug 9, 2023 | −$0.29 | −$0.38 | −30.23% | $0.00 | SEC |
| Q1 2023 | May 10, 2023 | −$0.44 | −$0.27 | +38.80% | $0.00 | SEC |
| Q4 2022 | Mar 7, 2023 | −$0.40 | −$0.49 | −23.52% | $0.00 | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.27 | −$0.42 | −55.56% | $0.00 | — |
| Q2 2022 | Aug 5, 2022 | −$0.23 | −$0.28 | −20.02% | −$140.00 | — |
| Q1 2022 | May 11, 2022 | −$0.23 | −$0.32 | −39.13% | $0.00 | — |
| Q4 2021 | Mar 22, 2022 | −$0.85 | −$0.52 | +38.82% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Nuvectis Pharma (NVCT) last report earnings?
Nuvectis Pharma last reported on Aug 5, 2025, covering fiscal Q2 2025.
Did NVCT beat earnings estimates?
No. Nuvectis Pharma reported EPS of −$0.30 for Q2 2025 against a −$0.25 estimate — a 19.19% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.